Literature DB >> 19012501

Voltage-gated sodium channels: the search for subtype-selective analgesics.

Steve England1.   

Abstract

BACKGROUND: Primary afferent or sensory neurons innervate almost all the tissues of the body. They are vital in receiving sensory information and conveying this to the spinal cord and subsequently to the brain, where the higher centres convert this afferent input into an 'understanding' of its nature. The nociceptors are a subset of sensory neurons responsible for the transmission of 'painful' stimuli into the CNS. OBJECTIVE/
METHODS: Voltage-gated sodium channels (VGSCs) are pivotal in the transduction of noxious signals at the terminals of the nociceptors and the transmission of the signal along the axon and into the spinal cord and brain. There are nine functional members of the VGSC family. This review aims to briefly summarise the biology of the family, discuss those VGSCs involved in the transduction and transmission of nociceptive signals and to highlight the potential and also the challenges in seeking subtype-selective VGSC modulators for the effective treatment of pain. RESULTS/
CONCLUSION: Robust evidence from preclinical models - and better yet, overwhelming human clinical genetic data - provides a compelling rationale for the involvement of VGSCs in nociceptive processing. Some compounds showing a low degree of subtype selectivity have been progressed into clinical development, but the results have been disappointing. It is likely that the high degree of structural homology within the VGSC family is a causative factor in making the discovery of subtype-selective modulators extremely challenging. A much greater understanding of the structure - function relationship for VGSCs and pharmacological modulators is needed if we are to design the compounds that will target those channels involved in nociceptive signalling whilst sparing those in the heart and brain. Only then will we be able to deliver a quantum leap in analgesic pharmacotherapy, providing the effective and well-tolerated drugs that the patient needs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19012501     DOI: 10.1517/13543780802514559

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  10 in total

Review 1.  Targeting voltage-gated sodium channels for treatment for chronic visceral pain.

Authors:  Fei-Hu Qi; You-Lang Zhou; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 2.  The discovery and development of analgesics: new mechanisms, new modalities.

Authors:  Gillian Burgess; Dic Williams
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 4.  Structure and function of μ-conotoxins, peptide-based sodium channel blockers with analgesic activity.

Authors:  Brad R Green; Grzegorz Bulaj; Raymond S Norton
Journal:  Future Med Chem       Date:  2014-10       Impact factor: 3.808

Review 5.  Translational pain research: achievements and challenges.

Authors:  Jianren Mao
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

6.  The role of continuous peripheral nerve blocks.

Authors:  José Aguirre; Alicia Del Moral; Irina Cobo; Alain Borgeat; Stephan Blumenthal
Journal:  Anesthesiol Res Pract       Date:  2012-06-18

Review 7.  Genes and epigenetic processes as prospective pain targets.

Authors:  Megan Crow; Franziska Denk; Stephen B McMahon
Journal:  Genome Med       Date:  2013-02-15       Impact factor: 11.117

8.  SDF1-CXCR4 signaling contributes to persistent pain and hypersensitivity via regulating excitability of primary nociceptive neurons: involvement of ERK-dependent Nav1.8 up-regulation.

Authors:  Fei Yang; Wei Sun; Yan Yang; Yan Wang; Chun-Li Li; Han Fu; Xiao-Liang Wang; Fan Yang; Ting He; Jun Chen
Journal:  J Neuroinflammation       Date:  2015-11-24       Impact factor: 8.322

Review 9.  Voltage gated sodium channels as drug discovery targets.

Authors:  Sharan K Bagal; Brian E Marron; Robert M Owen; R Ian Storer; Nigel A Swain
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

10.  A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Nav 1.8 inhibitor, in healthy adults.

Authors:  Hemme J Hijma; Emilie M J van Brummelen; Pieter S Siebenga; Geert Jan Groeneveld
Journal:  Clin Transl Sci       Date:  2021-12-27       Impact factor: 4.438

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.